

## Lifetime Achievement Award 2018


### Professor Thomas Barnes

The BAP Council is delighted to award the 2019 Lifetime Achievement Award to Professor Thomas Barnes. His research in psychopharmacology has been of immense importance and is recognised internationally. Thomas has been a tireless supporter of the BAP for many years and has made a huge contribution in terms of our teaching programme and guideline development. Thomas has also served as a Council Member, Secretary for External Affairs, and most notably as BAP President (2006-08).

Thomas was previously Professor of Clinical Psychiatry at Imperial College. His research in schizophrenia has extended over more than 40 years and encompassed the phenomenology and neuropsychology of schizophrenia, its association with comorbid substance use and the effectiveness and safety of antipsychotic medication throughout the course of the illness including in first episode psychosis and treatment-resistant schizophrenia. He has authored over 250 publications, introduced a series of antipsychotic side effect rating scales and been the chief or principal investigator in a series of influential RCTs. These include the pragmatic CULASS I and 2 trials which examined the effectiveness of first- and second-generation antipsychotic medications in schizophrenia and had a major impact on clinical practice. In terms of clinical work, he established one of the first units for treatment-resistant schizophrenia in the UK which offered a combination of pharmacological and psychosocial interventions and for many years he provided second-opinions on people with complex and challenging psychotic disorders.

Thomas founded and remains joint head of the UK Prescribing Observatory for Mental Health (POMH-UK), a quality improvement initiative based at The Royal College of Psychiatrists. Almost all UK mental health trusts regularly participate in POMH quality improvement programmes. He has been a member of many national committees and expert groups. Past appointments include membership of the Committee on Safety of Medicines, member of the National Institute for Health and Clinical Excellence (NICE) Schizophrenia Guideline Group, chair of the Special Interest Group for Psychopharmacology (Royal College of Psychiatrists) and President of the Royal Society of Medicine Psychiatry Section. Thomas is a regular reviewer for a wide range of journals and funding bodies and serves on the editorial boards of numerous journals.

Thomas is the lead author of the BAP 'Guideline for the pharmacological treatment of schizophrenia' ([https://www.bap.org.uk/pdfs/BAP\\_Guidelines-Schizophrenia.pdf](https://www.bap.org.uk/pdfs/BAP_Guidelines-Schizophrenia.pdf)). He has been a key member of other BAP guideline panels including the 2016 BAP 'Guidelines on the management



of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment' ([https://www.bap.org.uk/pdfs/BAP\\_Guidelines-Metabolic.pdf](https://www.bap.org.uk/pdfs/BAP_Guidelines-Metabolic.pdf)). Thomas has lectured on the BAP Clinical Certificate Course and the Masterclasses since their inception and his presentations always generate excellent feedback from the audience.

One of Thomas's greatest legacies is his unfailing support and encouragement to young clinicians and researchers in clinical and non-clinical work. He has inspired a generation of British psychiatrists, allied health care professionals and scientists to practice evidence-based medicine and pursue high quality research.

Council offers warm congratulations on behalf of BAP.